Entero Therapeutics, Inc. (ENTO) — Cash Flow-to-Debt Ratio
Entero Therapeutics, Inc. (ENTO) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of $-855.69K could theoretically repay 0% of its total liabilities ($45.81 Million) in one year. Check Entero Therapeutics, Inc. (ENTO) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Entero Therapeutics, Inc. Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Entero Therapeutics, Inc. across 12 annual periods. Also explore Entero Therapeutics, Inc. assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Entero Therapeutics, Inc. (2013–2024)
Year-by-year debt coverage analysis for Entero Therapeutics, Inc.. For market capitalisation and broader financial context, see Entero Therapeutics, Inc. (ENTO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.33x | $-9.22 Million | $27.61 Million | ▲ +91.2% |
| 2023 | -3.77x | $-12.38 Million | $3.28 Million | ▲ +54.4% |
| 2022 | -8.28x | $-22.34 Million | $2.70 Million | ▼ -403.1% |
| 2021 | -1.65x | $-32.29 Million | $19.61 Million | ▼ -128.4% |
| 2020 | -0.72x | $-11.22 Million | $15.56 Million | ▼ -21917.4% |
| 2019 | 0.00x | $-14.03K | $4.29 Million | ▲ +99.9% |
| 2018 | -3.63x | $-10.87 Million | $3.00 Million | ▼ -92.9% |
| 2017 | -1.88x | $-7.18 Million | $3.82 Million | ▼ -46.9% |
| 2016 | -1.28x | $-4.53 Million | $3.54 Million | ▼ -316700.7% |
| 2015 | 0.00x | $-4.17K | $10.32 Million | ▼ -57.0% |
| 2014 | 0.00x | $-1.01K | $3.93 Million | ▼ -100.4% |
| 2013 | 0.06x | $56.55 | $939.30 | — |